tbuckley/cabot-search huggingface dataset:
AB0850 Hyaluronic Acid in Osteoarthritis (OA) of Small Joints – the Results of Multicenter Randomized Placebo-Controlled 12-Months Study
Authors: E. Tsvetkova, L. Denisov, E. Nasonov, I. Menshikova, E. Shmidt, D. Goryachev
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Osteoarthritis (OA) is the most prevalent chronic articular disease, aggravating with age. OA is combined with such condition as IHD, arterial hypertension, diabetes mellitus, insult, osteoporosis and malignant neoplasm, which leads to difficulties in choosing adequate symptomatic therapy. <h3>Objectives</h3> Assessment of the efficacy, tolerability and period of aftereffect of the single administration into Ist carpometacarpal and Ist metatarsophalangeal joints of 1.0 ml (20mg) of hyaluronic acid, produced by NASHA technology (Durolane®) as compared with placebo. <h3>Methods</h3> The study included 120 pts (60 pts in experimental and control groups) of both sex older than 40 with OA of small hand joints or feet, pain intensity ?40 mm by VAS. The study consisted of two phases: "blind" phase up to 24 weeks, period of assessment of long term efficacy results – 48 weeks. The efficacy was assessed by 40% pain subsiding in analyzed joint, index dynamics AUSCAN (for the hand) daily dose of NSAID, total assessment of the effect separately by patient and therapist by VAS (mm). <h3>Results</h3> Both groups were comparable by basic clinical criteria. Average age of pts was 64.3 yrs (42-82), duration of OA of small joints – 5.0 yrs (3.0-10.0) and term of aggravation – 7.4 weeks. Experimental and control groups demonstrated prevailing of AH (61.7% and 58.3%), chronic gastritis (20% and 17%), diabetes mellitus (7% and 12%). 40% pain subsiding by VAS (mm) was noted in experimental group to 24th week in 79.7%, in the placebo group – 30% (chi-square: p&lt;10-5), relation of chances (OR) equal to 9.1 (3.9-21.1). Dispersion analysis (ANOVA for repeated measures) of pain, stiffness and function of AUSCAN index revealed reliable differences between Durolane and placebo, Reliable differences (p&lt;0.0001) according to assessment of general condition by the therapist and patient were found out in experimental group from the 4th week and were stable till 24th week. Adverse effects related to the therapy were not found. NSAID dose was decreased in 45.7% in experimental group and in 30% in placebo group. <h3>Conclusions</h3> High efficacy and considerable duration of aftereffect after single administration of Durolane SJ (small joints) as compared with placebo was demonstrated. After follow-up phase (48 weeks) additional data on long term effects will be reported. <h3>Disclosure of Interest</h3> None declared
Thrombocytopenic Purpura with Infectious Mononucleosis
Authors: T P Casey, J R Matthews
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PTH-307 Percutaneous management of pulmonary metastases arising from colorectal cancer; a systematic review
Authors: N Lyons, S Pathak, I Daniels, A Spiers, N Smart
Journal: Gut (2015)

<h3>Introduction</h3> Radiofrequency ablation (RFA) has been successfully utilised in the management of colorectal hepatic metastases and has also been used in the context of colorectal pulmonary metastases (CRPM). The aim was to systematically review the evidence and to assess the safety and efficacy of ablative techniques in the management of CRPM. <h3>Method</h3> A literature search was performed using PubMed, Embase, Cochrane Library, CINAHL and Google scholar databases to identify studies, which analysed ablative techniques and its efficacy in the management of CRPM. The primary outcomes of interest were overall survival and progression free survival. The secondary outcome measure was complication rates. <h3>Results</h3> 7 studies were included in the review with a total of 553 patients and all of which used RFA for ablation. Mortality from ablation was &lt;1% with overall survival ranging from 31–67 months. 1, 2 and 3 year survival ranges of 79–91%, 56–72% and 35–65% respectively. Local progression following ablation ranged from 9–22%. Major complication rates were noted in 1–8% of patients with minor complications ranging between 7–33%. 25% of patients required chest drain insertion post procedure. <h3>Conclusion</h3> This is the first paper to systematically review the use of RFA specifically for CRPM. This review provides evidence that RFA is a safe and effective technique for the management of CRPM. However in the absence of large randomised controlled trials it is unclear where RFA should sit in the treatment algorithm for patients with pulmonary metastases from colorectal primaries. <h3>Disclosure of interest</h3> None Declared.
PTU-205 The significance of elevated neutrophil: lymphocyte ratios in patients receiving chemoradiotherapy treatment for squamous cell carcinoma of the anus
Authors: R Bulla, D Humes, J Scholefield, CJ Walter
Journal: Gut (2015)

<h3>Introduction</h3> A recently published single-centre, retrospective study examined neutrophil:lymphocyte ratios (NLRs) in patients with squamous cell carcinoma of the anus and found a strong association with prognosis.<sup>1</sup> This study aimed to examine if the previously reported relationship between pretreatment NLRs and survival in patients undergoing chemoradiotherapy treatment of squamous cell carcinoma of the anus was also seen at our centre. <h3>Method</h3> All patients diagnosed with squamous cell carcinoma of the anus between 2005–2012 at Nottingham University Hospitals NHS Trust (NUH) were identified from the multidisciplinary team database. Retrospective data collection was undertaken using the electronic and case note records of those patients whose primary treatment was with chemoradiotherapy. The patients were divided into 2 groups: the non-elevated NLR group (NLR ≤5) and the elevated NLR group (NLR &gt;5). Their baseline demographics and mortality were compared. <h3>Results</h3> Seventy-six patients (50 female and 26 male) with a median age of 63 years (IQR 52–74) were treated at NUH for squamous cell carcinoma of the anus with chemoradiotherapy over the 8-year study period. Of these 15 (20%) demonstrated an elevated NLR at presentation. There was no significant difference in baseline demographics and follow-up times between the non-elevated and elevated NLR groups with median clinical follow-up of 36 months (IQR 24–52) and 38 months (IQR 12–44) (p = 0.4) respectively. On univariate analysis the elevated NLR group was associated with worse survival with a hazard ratio (HR) for mortality of 2.73 (95% CI 1.07–6.96). Multivariate analysis of mortality adjusting for the known confounders of age, sex and stage of disease demonstrated a HR 6.21 (95% CI 1.98–19.47). <h3>Conclusion</h3> In this study a fifth of patients with squamous cell carcinoma of the anus demonstrated elevated NLRs at presentation. Elevated NLRs at presentation were associated with increased mortality. This association strengthened when adjusting for stage of disease at presentation. <h3>Disclosure of interest</h3> None Declared. <h3>Reference</h3> Toh E, Wilson J, Sebag-Montefiore D, Botterill I. Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus. Colorectal Dis. 2014;16(3):90–7
AB0630 Follow up of Patients with GCA Indicates Inadequacy of Currently Employed Treatment Strategy: Table 1.
Authors: A. Hočevar, R. Ješe, Ž. Rotar, M. Tomšič
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Glucocorticoids remain the gold standard treatment for giant cell arteritis (GCA). However, the relapses and recurrences in GCA are frequently reported. <h3>Objectives</h3> To determine the effectiveness of standard GCA treatment at the single secondary/tertiary rheumatology center. <h3>Methods</h3> We prospectively followed patients diagnosed with GCA between 01.09.2011 and 31.08.2014 at our center. Follow up visits with predetermined clinical and laboratory tests were performed 12, 24, 48 and 96-weeks after diagnosis. All patients who completed at least the first follow up visit were included in the analysis. All patients were treated in line with the EULAR recommendations (Ann Rheum Dis 2009;68:318-23). In short, patients with uncomplicated GCA were treated with initial oral methylprednisolone (MP) 32–48 mg qd, while the patients with ischemic complications or involvement of large vessels first received MP 250 mg on 3 consecutive days intravenously. MP tapering was started 2–4 weeks after treatment initiation slowly to 4 mg qd which was continued for at least 1.5 years. In patients who relapsed during the MP tapering unscheduled visits were arranged and treatment was adjusted. A patient was said to have a relapse if symptoms or signs characteristic of GCA reoccurred or an increase of markers of inflammation that could not be explained by another disease was noted. <h3>Results</h3> During the observation period 71 (72% female) new GCA cases were identified, with a median (IQR) age 73.1 (67.0–77.1) years and symptom duration 30 (14–84) days. One patient died of cancer during the initial diagnostic work-up, 1 refused the treatment and 1 was lost to follow up. The remaining 68 (95.8%) patients were followed for a median (IQR) 63 (49–111) weeks. During the follow up 29/68 patients relapsed based on clinical (5/29), laboratory (14/29), both clinical and laboratory (10/29) findings. None of the patients suffered visual loss at relapse. Median (IQR) time to relapse was 26.6 (13.4–26.6) weeks. Median (IQR) MP dose at relapse was 6.5 (4.0–12.5) mg. Patients who relapsed had a significantly higher systemic inflammatory activity at baseline (Table 1). Treatment adjustments in patients who relapsed included a temporary increase of MP dose (29/29), and add-on therapy with leflunomide 20 mg qd (15/29) or weekly methotrexate (2/29). <h3>Conclusions</h3> Even in the short term the glucocorticoids in monotherapy might be inadequate for a sustained remission in GCA. <h3>Disclosure of Interest</h3> None declared
(Z)-3,5,4′-Trimethoxystilbene Limits Hepatitis C and Cancer Pathophysiology by Blocking Microtubule Dynamics and Cell-Cycle Progression
Authors: Charles B. Nguyen, Hari Kotturi, Gulam Waris, Altaf Mohammed, Parthasarathy Chandrakesan, Randal May, Sripathi Sureban, Nathaniel Weygant, Dongfeng Qu, Chinthalapally V. Rao, Danny N. Dhanasekaran, Michael S. Bronze, Courtney W. Houchen, Naushad Ali
Journal: Cancer Research (2016)

Hepatocellular carcinoma (HCC) is the third most common cause of cancer-related deaths worldwide. Chronic hepatitis C virus (HCV) infection causes induction of several tumors/cancer stem cell (CSC) markers and is known to be a major risk factor for development of HCC. Therefore, drugs that simultaneously target viral replication and CSC properties are needed for a risk-free treatment of advanced stage liver diseases, including HCC. Here, we demonstrated that (Z)-3,5,4'-trimethoxystilbene (Z-TMS) exhibits potent antitumor and anti-HCV activities without exhibiting cytotoxicity to human hepatocytes in vitro or in mice livers. Diethylnitrosamine (DEN)/carbon tetrachloride (CCl4) extensively induced expression of DCLK1 (a CSC marker) in the livers of C57BL/6 mice following hepatic injury. Z-TMS exhibited hepatoprotective effects against DEN/CCl4-induced injury by reducing DCLK1 expression and improving histologic outcomes. The drug caused bundling of DCLK1 with microtubules and blocked cell-cycle progression at G2-M phase in hepatoma cells via downregulation of CDK1, induction of p21(cip1/waf1) expression, and inhibition of Akt (Ser(473)) phosphorylation. Z-TMS also inhibited proliferation of erlotinib-resistant lung adenocarcinoma cells (H1975) bearing the T790M EGFR mutation, most likely by promoting autophagy and nuclear fragmentation. In conclusion, Z-TMS appears to be a unique therapeutic agent targeting HCV and concurrently eliminating cells with neoplastic potential during chronic liver diseases, including HCC. It may also be a valuable drug for targeting drug-resistant carcinomas and cancers of the lungs, pancreas, colon, and intestine, in which DCLK1 is involved in tumorigenesis. Cancer Res; 76(16); 4887-96. ©2016 AACR.
Management of Primary Central Nervous System Lymphoma
Authors: Francois G. El Kamar, Lauren E. Abrey
Journal: Journal of the National Comprehensive Cancer Network (2004)

Primary central nervous system lymphoma (PCNSL) is a unique subtype of non-Hodgkin's lymphoma (NHL). Although PCNSL is both chemosensitive and radiosensitive, it is very difficult to treat and outcomes are substantially inferior when compared with similar extranodal NHL. Furthermore, as a subtype of brain tumors and NHL, the overall incidence has been increasing over the past several decades. This review summarizes the salient clinical features and approach to management of the immunocompetent patient with PCNSL.
Enzyme Changes Induced in Normal and Malignant Tissues with Chemical Agents. VI. Effect of Acetylpodophyl-Iotoxin-ω-Pyridinium Chloride on Malic-Oxidase and on Isocitric-Oxidase Systems of Sarcoma 37&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: V S WARAVDEKAR, O POWERS, J LEITER
Journal: JNCI Journal of the National Cancer Institute (1956)

Enzyme Changes Induced in Normal and Malignant Tissues with Chemical Agents. VI. Effect of Acetylpodophyl-Iotoxin-ω-Pyridinium Chloride on Malic-Oxidase and on Isocitric-Oxidase Systems of Sarcoma 37 Get access V. S. Waravdekar, V. S. Waravdekar Laboratory of Chemical Pharmacology, National Cancer Institute,4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar O. Powers, O. Powers Laboratory of Chemical Pharmacology, National Cancer Institute,4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar J. Leiter J. Leiter Laboratory of Chemical Pharmacology, National Cancer Institute,4Bethesda, Md. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 6, June 1956, Pages 1443–1452, https://doi.org/10.1093/jnci/16.6.1443 Published: 01 June 1956 Article history Received: 16 January 1956 Published: 01 June 1956
The Disappearance Of Sulfhemoglobin in the Blood as a Measure of the Life Span of Erythrocytes in Normal Rabbits and Mice and in Tumor-Bearing Mice&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: K S DOD, H R BIERMAN, M B SHIMKIN
Journal: JNCI Journal of the National Cancer Institute (1951)

The Disappearance Of Sulfhemoglobin in the Blood as a Measure of the Life Span of Erythrocytes in Normal Rabbits and Mice and in Tumor-Bearing Mice Get access Kenneth S. Dod, Kenneth S. Dod Search for other works by this author on: Oxford Academic PubMed Google Scholar Howard R. Bierman, Howard R. Bierman Search for other works by this author on: Oxford Academic PubMed Google Scholar Michael B. Shimkin Michael B. Shimkin Laboratory of Experimental Oncology, National Cancer Institute, National Institutes of Health, U. S. Public Health Service, and the Division of Medicine, University of California School of Medicine, San Francisco, Calif. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 11, Issue 6, June 1951, Pages 1093–1103, https://doi.org/10.1093/jnci/11.6.1093 Published: 01 June 1951 Article history Received: 21 December 1950 Published: 01 June 1951
Generalized pustular psoriasis.
Authors: R DEGOS, E LORTAT-JACOB, J DURAND
Journal: BMJ (1972)

of neoplasms and the meaning of pathological terms.Thus, "restorative hyperplasia" is regarded as a better term than "regeneration," and "nodular hyperplasia" is preferred to "regeneration nodules."A particularly important recom- mendation is that, in relation to liver cancer in man, priority should now be given to assessing the role of known or suspected hepatocarcinogens rather than to in- creasing the already bewilderingly large number of liver carcinogens listed during the conference by G. P. Warwick.'
SAT0492 Trends and Predictors of Mortality in Childhood Onset Lupus Over Twenty Four Years: A North Indian Single Centre Experience
Authors: B. Abujam, A. Gupta, D. Suri, A. Rawat, S. Singh
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic lupus erythematosus is associated with poorer survival in developing countries in adults. However, there is limited data on survival and causes of death in childhood lupus <h3>Objectives</h3> To identify cause, time-trends and predictors of mortality in North Indian children with SLE. <h3>Methods</h3> This study included patients with childhood onset lupus who were diagnosed at a North Indian Federally funded university hospital from 1991 to 2014. Patients were included in this study if they fulfilled the ACR 1997 revised criteria for systemic lupus erythematosus and were below the age of 14 years on presentation. Clinical data was extracted from the medical records, to identify etiology in children who had died. To compare time trends of mortality, we divided patients into three cohorts on their year of presentation, i.e. 1991-1998, 1999-2006 and 2007-2013. Survival was estimated by Kaplan-meier analysis and compared using log-rank test. Univariate and multivariate analysis for predictors of mortality was done by cox-regression. <h3>Results</h3> Among the 124 patients with childhood onset SLE who presented to our center, there were 24 deaths (20%). Eleven of these patients (46%) died at the initial visit or within 3 months of presentation. 1, 5 and 10 year survival was 88.3, 77.5 and 70.9% respectively. Common cause of death was presence of both infection and disease activity (42%). Among 11 patients with infection as a cause of death, sepsis, commonly polymicrobial or gram negative, occurred in 7, CNS tuberculosis in 2 and invasive fungal infection in 2. Disease activity related causes of death included active nephritis in 12, NPSLE in 3 and one case of myocarditis, diffuse alveolar hemorrhage and macrophage activation syndrome. The only baseline characteristic, which was a predictor of survival, was serum creatinine (hazard ratio 2.9 (95% CI 1.3 to 6.5)). There was a significant increase in survival from 1992-1998 to 1999-2006 (Figure 1). This was mainly contributed by the major decline in the proportion of patients who died at initial presentation from 25% to 8% in 1992-1998 and 1999-2006 respectively. <h3>Conclusions</h3> This cohort of childhood lupus from a center in a developing country found an overall mortality in 20%, with almost half of these occuring at presentation. Presence of active disease and infection were the most common causes. However, there has been an improvement of survival with time. <h3>Disclosure of Interest</h3> None declared
High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort
Authors: Meghna Jani, John D Isaacs, Ann W Morgan, Anthony G Wilson, Darren Plant, Kimme L Hyrich, Hector Chinoy, Anne Barton
Journal: Annals of the Rheumatic Diseases (2016)

Objectives To evaluate (i) the association between random certolizumab drug levels, antidrug antibodies (ADAbs) and treatment response in patients with rheumatoid arthritis (RA); (ii) longitudinal factors associated with ADAbs and certolizumab drug levels. Methods This prospective cohort included 115 patients with RA treated with certolizumab. Serum samples were collected at 3, 6 and 12 months following treatment initiation. Drug levels and ADAbs were measured using ELISA and radioimmunoassay, respectively, at 3, 6 and 12 months. Disease Activity Score in 28 joints (DAS28) were measured at each visit and 12 months European League Against Rheumatism (EULAR) response was calculated. Patient self-reported adherence was collected longitudinally. Ordinal logistic regression and generalised estimating equation were used to test the association: (i) between drug levels, from serum sampled and treatment response; (ii) between ADAbs and drug levels; (iii) patient-centred factors and drug levels. Results ADAbs were detected in 37% (42/112 patients by 12 months). The presence of ADAbs were significantly associated with lower drug levels over 12 months (β=−0.037, 95% CI −0.055 to 0.018, p&lt;0.0001) but not independently with 12 months EULAR response (β=0.0013 (95% CI −0.0032 to 0.00061), p=0.18). Drug level was associated with 12 months EULAR response (β=0.032 (95% CI 0.0011 to 0.063), p=0.042). In the multivariate model, ADAb level and adherence were significantly associated with drug concentrations. Conclusions This is the first study to demonstrate that higher certolizumab drug levels are associated with better 12 months EULAR response. ADAbs in certolizumab-treated patients with RA were detected at higher levels than previous studies and help determine the aetiology of a low drug level.